Viking Therapeutics Stock Gains Momentum on Promising Clinical Data

Viking Therapeutics US92686J1060

Shares of Viking Therapeutics experienced a significant rally in today’s trading session, marking a notable recovery after a volatile period in 2025. The upward movement is fueled by encouraging clinical trial results for its GLP-1 candidate, VK2735, and strategic steps toward potential future commercialization.

The equity advanced by 7.24%, or $2.31, to close at $34.17. During the session, it traded between $31.71 and $34.28, rebounding from the previous day’s close of $31.86. Trading volume reached approximately 2.76 million shares, which remains below the 3.53 million average.